Phase II study of the novel antifolate agent pralatrexate in combination with the histone deacetylase inhibitor romidepsin for the treatment of patients with mature T-cell lymphoma

Ryu Tiger, Y. K., Jain, S., Barta, S. K., Tolu, S., Estrella, B., Sawas, A., Lue, J. K., Francescone, M. M., Pro, B., & Amengual, J. E. (2024). Phase II study of the novel antifolate agent pralatrexate in combination with the histone deacetylase inhibitor romidepsin for the treatment of patients with mature T-cell lymphoma. Leukemia & Lymphoma, 65(6), 736–745. https://doi.org/10.1080/10428194.2024.2329996
Authors:
Yun Kyoung Ryu Tiger
Salvia Jain
Stefan K Barta
Seda Tolu
Brian Estrella
Ahmed Sawas
Jennifer K Lue
Mark M Francescone
Barbara Pro
Jennifer E Amengual
Affiliated Authors:
Yun Kyoung Ryu Tiger
Seda Tolu
Brian Estrella
Ahmed Sawas
Mark M Francescone
Barbara Pro
Jennifer E Amengual
Author Keywords:
chemotherapeutic approaches
lymphoma and hodgkin disease
clinical results
t-cell lymphoma
epigenetics
antifolate
Publication Type:
Article
Unique ID:
10.1080/10428194.2024.2329996
PMID:
Publication Date:
Data Source:
PubMed

Record Created: